

Mirati Therapeutics, Inc.  
Form 8-K  
September 10, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 9, 2015**

---

**MIRATI THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State of incorporation)

**001-35921**  
(Commission File No.)

**46-2693615**  
(IRS Employer Identification No.)

**9393 Towne Centre Drive, Suite 200**

Edgar Filing: Mirati Therapeutics, Inc. - Form 8-K

San Diego, California 92121

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(858) 332-3410**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On September 9, 2015 Mirati Therapeutics, Inc. (the Company ) presented data at the International Association of Lung Cancer 16th World Conference on Lung Cancer (the Conference ) on the first non-small cell lung cancer ( NSCLC ) patient with *AXL* gene amplification enrolled in the MGCD265 Phase 1b expansion cohort. The data presented showed the patient had a confirmed Partial Response ( PR ) based on RECIST criteria. Additionally the Company provided an interim update on the ongoing MGCD265 Phase 1b expansion cohort disclosing that 2 of the 4 NSCLC patients who are currently evaluable (having had at least 1 on-treatment scan) have confirmed PRs based upon RECIST criteria including the patient with *AXL* amplification highlighted above and a patient with *MET* gene amplification. Both of the patients with confirmed PRs remain on study. As of September 1, 2015, 9 patients with genetic alterations in *Met* or *AXL* have been enrolled in the expansion cohort, including 7 with NSCLC and 2 with other solid tumors. Of the 9 patients enrolled 7 remain on study for up to 8+ months. The Company plans to provide a more in-depth update on this study when more data is available.

On September 9, 2015, the Company issued a press release announcing the data to be presented at the Conference. A copy of the press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated September 9, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 10, 2015

**MIRATI THERAPEUTICS, INC.**

By:

/s/ Mark J. Gergen  
Mark J. Gergen  
Executive Vice President and Chief Operations  
Officer

**INDEX TO EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated September 9, 2015.